Physician profile
Maredy Sar
NPI 1598368045
$2,555.15
in general payments reported to CMS, 2019-2025
17 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.64 · 2023: $81.44 · 2024: $621 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,165.36 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $239.45 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $232.71 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.72 | 2024-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $118.54 | 2025 | Rexulti |
| Pfizer INC. | $116.14 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.54 | 2025 | |
| Exact Sciences Corporation | $96.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $60.34 | 2025 | Rexulti |
| Amgen INC. | $53.26 | 2025 | Evenity |
| Seqirus USA INC | $27.88 | 2025 | Fluad, Flucelvax |
| Novo Nordisk INC | $27.01 | 2025 | Ozempic |
| Gilead Sciences, INC. | $22.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.64 | 2022 | |
| Hologic Sales and Service, LLC | $21.01 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $18.90 | 2024 | |
| Echosens North America, INC. | $15.63 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maredy Sar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.